Omnicell (NASDAQ:OMCL) Receives Neutral Rating from Bank of America

Bank of America restated their neutral rating on shares of Omnicell (NASDAQ:OMCL) in a research report report published on Thursday morning, Marketbeat.com reports. They currently have a $57.00 target price on the stock, up from their previous target price of $44.00.

Other equities research analysts have also issued research reports about the company. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and boosted their target price for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Wells Fargo & Company upped their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Benchmark reissued a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. raised their target price on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 23rd. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and an average price target of $49.14.

Omnicell Price Performance

Shares of NASDAQ OMCL traded down $0.27 during mid-day trading on Thursday, hitting $48.37. 21,262 shares of the stock traded hands, compared to its average volume of 525,021. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.74. The firm has a 50 day simple moving average of $43.26 and a two-hundred day simple moving average of $35.17. The company has a current ratio of 1.05, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The business had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. During the same period last year, the company earned $0.29 EPS. The firm’s revenue was down 7.4% compared to the same quarter last year. Research analysts anticipate that Omnicell will post 0.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Summit Global Investments bought a new stake in shares of Omnicell during the 3rd quarter worth $221,000. QRG Capital Management Inc. purchased a new position in Omnicell in the third quarter valued at about $231,000. Rice Hall James & Associates LLC bought a new position in shares of Omnicell during the 3rd quarter valued at approximately $2,723,000. 1620 Investment Advisors Inc. increased its stake in shares of Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Roubaix Capital LLC purchased a new stake in shares of Omnicell during the 3rd quarter worth approximately $1,851,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.